Cyclerion Therapeutics, Inc.

Cyclerion Therapeutics, Inc. filed an amendment to its Form 10-K to include information required by Part III (Items 10-14), as it does not intend to file an annual meeting definitive proxy statement. The amendment also reiterates the previously announced proposed merger with Korsana Biosciences, Inc., which is expected to close in Q3 2026, pending shareholder approvals. The filing details the company's board of directors, executive compensation, corporate governance, and committee structures.